The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors

Am J Clin Oncol. 2013 Feb;36(1):89-90. doi: 10.1097/COC.0b013e31827a7f55.

Abstract

Although adjuvant imatinib (IM) for high risk GIST is an accepted treatment consideration, the duration of therapy remains controversial. The recently published SSGXVIII/AIO randomized clinical trial of 3 years vs. 1 year of adjuvant IM has established a benefit of RFS and OS for the 3 year cohort. Future studies are necessary to continue to further delineate risk variables for GIST recurrence.

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Benzamides
  • Chemotherapy, Adjuvant / methods*
  • Clinical Trials, Phase III as Topic*
  • Gastrointestinal Stromal Tumors / drug therapy*
  • Gastrointestinal Stromal Tumors / mortality
  • Humans
  • Imatinib Mesylate
  • Piperazines / administration & dosage*
  • Practice Guidelines as Topic*
  • Pyrimidines / administration & dosage*
  • Randomized Controlled Trials as Topic*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate